"Rivaroxaban" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.
| Descriptor ID |
D000069552
|
| MeSH Number(s) |
D02.886.778.727 D03.383.533.640.713 D03.383.903.727
|
| Concept/Terms |
Rivaroxaban- Rivaroxaban
- 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide
|
Below are MeSH descriptors whose meaning is more general than "Rivaroxaban".
Below are MeSH descriptors whose meaning is more specific than "Rivaroxaban".
This graph shows the total number of publications written about "Rivaroxaban" by people in this website by year, and whether "Rivaroxaban" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2016 | 3 | 0 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 0 | 2 |
| 2020 | 3 | 1 | 4 |
| 2021 | 2 | 1 | 3 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rivaroxaban" by people in Profiles.
-
In vitro effects of Gla-domainless factor Xa analog on procoagulant and fibrinolytic pathways in apixaban-treated plasma and whole blood. Thromb Res. 2023 Oct; 230:119-125.
-
Anticoagulant Therapy for Mechanical Heart Valves - Unmet Need Persists. NEJM Evid. 2023 Jul; 2(7):EVIDe2300106.
-
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. J Am Heart Assoc. 2022 10 18; 11(20):e026229.
-
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 05 10; 145(19):1471-1479.
-
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. J Am Heart Assoc. 2021 11 16; 10(22):e021579.
-
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. J Thromb Haemost. 2021 11; 19(11):2772-2780.
-
Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era. Semin Respir Crit Care Med. 2021 04; 42(2):308-315.
-
Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. Clin Appl Thromb Hemost. 2021 Jan-Dec; 27:10760296211053316.
-
Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis. J Thromb Thrombolysis. 2020 Nov; 50(4):913-920.
-
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J Am Coll Cardiol. 2020 06 30; 75(25):3140-3147.